When a child is diagnosed with cancer, their family is presented with treatment options – often a combination of surgery, radiation and chemotherapy. Radiation and chemotherapy have been used to treat kids’ cancers for more than 50 years and often come with long-term late effects including secondary cancers, heart damage and cognitive issues. Often a child’s best chance at survival is a clinical trial which offers them the newest treatment options available.
In recognition of Childhood Cancer Awareness Month, the St. Baldrick’s Foundation will highlight the critical need to fund lifesaving research and share stories of kids affected by cancer – like Micah, who is alive today because there was a clinical trial available.
To view the multimedia release go to:
https://www.multivu.com/players/English/8284352-st-baldricks-foundation-conquer-childhood-cancers/
Cancun spring break can prove to be great one for couples and families seeking some quality time together. For some Cancun has also proved to be a therapeutic center as it provides some excellent treatment for people recovering from ailments.
WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced the winners of its 2016 Health Hero Awards (http://www.webmd.com/healthheroes/what-is-hero), recognizing individuals who are changing the healthcare landscape by meeting a health challenge and giving back to others. This year’s winners are Seth Rogen and Lauren Miller Rogen, Ed Damiano, PhD, Betty Ferrell, RN, PhD and Trisha Prabhu.
On November 3, 2016, an accomplished and inspiring lineup of presenters and performers will gather to honor the winners at the 3rd Annual WebMD Health Hero Awards gala, hosted by Good Morning America co-anchor Robin Roberts. This year’s presenters include David Krumholtz, Adam Savage, and Sarah Wynter, with musical performances by A Great Big World and Naturally 7.
To watch the red carpet arrivals as they happen live from the TimesCenter in New York City, follow WebMD on www.facebook.com/webmd beginning at 6:30 PM ET on November 3, and be sure to follow @WebMD on Instagram, Snapchat and Twitter for updates throughout the night with #HealthHeroes.
To view the multimedia release go to:
http://www.multivu.com/players/English/7579756-webmd-2016-health-hero-awards/
Significant advances toward cures for blood cancer patients, many of which were funded by The Leukemia & Lymphoma Society (LLS) over the past 65 years, are among the dramatic highlights featured in Ken Burns presents CANCER: THE EMPEROR OF ALL MALADIES, a film by Barak Goodman, to air on PBS stations nationwide from March 30-April 1. The documentary series is based on the Pulitzer Prize-winning book by Siddhartha Mukherjee, MD, The Emperor of All Maladies: A Biography of Cancer.
LLS has been a driving force behind treatment breakthroughs for patients with blood cancers, including leukemia, lymphoma and myeloma. As the world’s largest voluntary health agency dedicated to finding cures for blood cancer patients, LLS has invested more than $1billion in research to advance lifesaving treatments and cures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7409151-lls-cancer-research-pbs-series/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Extremely painful and destructive, gout is the most common form of inflammatory arthritis with elevated serum uric acid (sUA) a root cause of the disease. Even with the growing incidence of gout, recent research from the Gout & Uric Acid Education Society (GUAES) found that just 16 percent of Americans overall know the target sUA number for gout (6 mg/dL or below) – and just 38 percent of people with gout had their sUA levels checked within the past six months, the timeframe recommended by the American College of Rheumatology. Additionally, the majority of gout sufferers don’t understand the importance of taking daily uric acid-lowering medications, with four in 10 incorrectly believing that they can stop taking medications when they aren’t experiencing flares.
Seeking to increase recognition of the severity of gout and need for routine sUA testing and management, GUAES hosted a professional roundtable discussion on October 3, 2015. The roundtable brought together several experts – rheumatologists, a family care physician, and representatives from the American Association of Diabetes Educators, the National Kidney Foundation and CreakyJoints – to explore how to more effectively educate about gout and improve access to public education and treatment.
To view the multimedia release go to:
http://www.multivu.com/players/English/7715851-guaes-gout-roundtable-discussion/
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
For North America
Dr. Danielle Marcoux from Canada
Camp Liberté – Summer camp for children with skin disorders
This one-week summer camp run by volunteer dermatologists and nurses enrolled children aged 7 to 12 with moderate-to-severe skin disorders, as well as their families, to bring them together for support, social interaction and to increase their confidence. All the activities aim to increase patients’ confidence and self-esteem, improve social skills, reduce stigma about their condition and improve adherence to treatment.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
This week Hill-Rom (NYSE: HRC) is featuring the Progressa® bed system, the next generation of intensive care unit (ICU) bed systems, at the American Organization of Nurse Executives (AONE) annual meeting in Orlando, Fla. The Progressa bed system is a therapeutic system designed to treat and prevent complications of immobility. It features a state-of-the-art design that supports treatment goals and was engineered to help address patient migration via its StayInPlace™ technology.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/66137-hill-rom-new-progressa-bed-system
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
Ahead of World Mental Health Day, today sees the publication of the Mental Health Integration Index, a new research initiative commissioned by the Janssen Pharmaceutical Companies of Johnson & Johnson and undertaken by the Economist Intelligence Unit.1 The research explores the challenges of integrating Europeans with mental illness into society and employment, within the European Union’s 28 Member States, plus Norway and Switzerland. Countries have been ranked according to their degree of commitment to support those living with mental illness; the findings demonstrate that while there are many examples of good practice across Europe, the whole region has a long way to go before people with mental illness are adequately supported and truly integrated into their communities.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/72762557-janssen-europe-mental-health-index/
In recognition of Metastatic Breast Cancer Awareness Day on October 13, AstraZeneca (NYSE: AZN) is raising awareness about the thousands of U.S. women living with metastatic breast cancer. Metastatic Breast Cancer Awareness Day seeks to generate attention and greater support for women living with metastatic breast cancer among the public and stakeholders within the breast cancer community and more research to extend lives.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58129-mbc-awareness
Abbott announced today the U.S. Food and Drug Administration approval and launch of the iDesign Advanced WaveScan Studio System. The system acts as the "brain" of the LASIK procedure, generating a high-definition scan that measures and maps irregularities of the eye that may impact vision. From these measurements, the iDesign System creates an accurate and personalized LASIK treatment plan based on the unique "blueprint" of each person’s eyes.
The iDesign System captures more than 1,200 micro readings of the eye, as well as identifying the shape of the cornea, its curvature, how light passes through the eye and pupil diameter under different lighting conditions – all in one, three-second scan that can be used to precisely correct vision.
The development of the sensor technology within the iDesign System was the result of an earlier discovery by Abbott scientists, which NASA used to accurately measure and shape the mirrors in the James Webb Space Telescope to ensure it will transmit high resolution images of deep space back to earth. The telescope is scheduled to launch in 2018.
To view the Multimedia News Release, please go to http://www.multivu.com/players/English/7571951-abbott-idesign-system-3-d-eye-map/
